CHMP5 and COVID-19: The data presented in this work identify LSR as a therapeutic target in the management of COVID-19 and open up new avenues for blocking the binding of Spike to ACE2 through LSR for the prevention of infection with SARS-CoV-2 as well as other viruses that use ACE2 for cell entry.